Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al

Affiliations

¹ Department of Health Sciences Research. Electronic address: maurer.matthew@mayo.edu.
² Division of Hematology, Mayo Clinic, Rochester, USA.

Free article

Comment

M J Maurer et al. Ann Oncol. 2019.

Free article

. 2019 Jan 1;30(1):153.

doi: 10.1093/annonc/mdy492.

¹ Department of Health Sciences Research. Electronic address: maurer.matthew@mayo.edu.
² Division of Hematology, Mayo Clinic, Rochester, USA.

No abstract available

Comment on

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B. Maurer MJ, et al. Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203. Ann Oncol. 2018. PMID: 29897404 Free PMC article.
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting.
van der Galiën HT, Hoogendoorn M, Kibbelaar RE, van Meerten T, van Rijn RS. van der Galiën HT, et al. Ann Oncol. 2019 Jan 1;30(1):151-152. doi: 10.1093/annonc/mdy482. Ann Oncol. 2019. PMID: 30364941 No abstract available.